Breakthrough: New blood test for early detection of Alzheimer's disease

Over 55 million people across the globe are living with Alzheimer’s, according to recent statistics from the World Health Organization, and many struggle to access the right diagnostic test early on.

Symptoms can be subtle at first, and many folks only receive clarity on their condition well after harmful changes have already taken root.

Dr. Marc Suárez-Calvet, a neurologist at Hospital del Mar and researcher at the Barcelonaβeta Brain Research Center (BBRC), has spent years focused on ways to measure Alzheimer’s markers in routine clinical settings.

Recent work by his team and others suggests that a streamlined blood test may be able to show whether someone is at risk, even in the presence of mild forgetfulness or general cognitive changes.

Why early detection matters

Alzheimer’s is notorious for hiding behind familiar signs of aging, and that overlap can be confusing for families.

Many older adults dismiss memory slips as nothing unusual, but doctors now caution that missing an early diagnosis can limit treatment options.

Studies highlight that advanced tools, including positron emission tomography (PET) scans, can confirm Alzheimer’s pathology with fair accuracy.

Yet these scans can be expensive, inconvenient for those living in remote areas and limited by availability in many regions.

How the test identifies Alzheimer’s

The promising test zeroes in on a biomarker in the blood, called phospho-tau217 (p-tau217). Scientists have discovered that unusual shifts in this marker might be tied to the Alzheimer’s process well before pronounced memory issues emerge.

“This development may allow us to determine who needs to undergo further tests, such as a lumbar puncture or a PET scan, and who doesn’t,” stated Dr. Suárez-Calvet.

Experts believe that routine labs could run the p-tau217 test on fully automated platforms, making advanced evaluation more accessible to smaller clinics.

Blood test is easier and faster

Blood tests are generally easier on patients than procedures like a spinal tap, which draws cerebrospinal fluid (CSF). Some people hesitate to get a lumbar puncture because of discomfort, cost or personal fears.

“Our results, combined with the ease of use and implementation of this type of test, could facilitate its integration into clinical practice,” said BBRC researcher Dr. Federica Anastasi. Researchers also note that blood-based tests can be done at many local labs. 

Alzheimer’s test limits over age 80

Doctors caution that accuracy decreases slightly in individuals past the age of 80 if only a single cutoff measure is used.

That doesn’t mean the test fails; it just suggests the need for an additional step to ensure that results line up with each patient’s full health profile.

Older patients might have other changes that affect test readings, such as chronic kidney disease (CKD) or coexisting conditions that overlap with cognitive symptoms.

By factoring these elements into the analysis, clinicians can keep the test from overestimating or underestimating risk.

Two cutoffs for extra clarity

Scientists recommend using two separate thresholds for p-tau217. In many cases, a higher value points toward clear Alzheimer’s risk, and a lower value suggests an all-clear.

People who land in the middle range are flagged for more detailed evaluation. This avoids confusion and ensures those on the borderline get an extra look using other diagnostic tools.

Economic advantages

Costs linked to diagnosing Alzheimer’s can add up quickly, due to extra imaging tests and possible prolonged hospital stays.

By offering a blood-based evaluation, doctors and patients may reduce the need for more expensive scans in many situations.

Estimates show that a simple lab draw for Alzheimer’s markers can cut typical diagnostic costs by more than half.

Although further confirmation might be needed for some, the savings could be a big deal in large-scale healthcare planning.

Alzheimer’s test improves small-town access

Primary care offices rarely have the specialized equipment or staff needed for advanced imaging. With a user-friendly blood analysis, people in smaller towns might not have to travel several hours to major medical centers.

This shift can also ease overcrowding at specialized hospitals, allowing neurologists and geriatricians to focus on complex cases.

The blood test, in combination with standard exams, can give family doctors a reliable starting point without the wait times that often plague bigger clinics.

Future directions

Experts caution that this test isn’t meant to replace clinical judgment. They emphasize that doctors who see potential warning signs still have to look at a patient’s history, neurological exams and overall health.

Researchers plan more studies to understand how factors like diabetes and advanced age can skew results. Some teams aim to fine-tune the test so that even borderline cases get a more precise reading within standard blood panels.

Staying one step ahead

Many caregivers say that when Alzheimer’s is confirmed sooner, they can plan better for therapy, lifestyle adjustments and family support.

Catching things early also opens the door for experimental treatments aimed at slowing disease progression.

A widely accessible test for Alzheimer’s risk holds promise for bridging the gaps in rural and underserved communities.

Even so, professionals emphasize the need for continued innovation to improve reliability for every age bracket and health background.

The study is published in Nature Medicine.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–